bDMARDs: Rheumatology resources now available
NPS MedicineWise is leading a consortium of nine organisations, including SHPA, in a three-year project funded by the Australian Government Department of Health. The program aims to support safe and wise therapeutic decisions about bDMARDs and other specialised medicines across a range of rheumatology, dermatology, gastroenterology, immunology and oncology indications.
Rheumatology resources are now available for health professionals and consumers. We encourage you to have a look at the resources SHPA has been involved in developing. Over the coming months we will announce new resources for inflammatory bowel disease.
World-first ‘living guidelines’ for inflammatory arthritis
Focusing on rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis and developed by the Australia and New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC), these living guidelines are informing the development of resources, tools and interventions to help pharmacists, other health professionals and consumers to achieve the best possible health outcomes.
Resources for pharmacists
Resources for pharmacists including webinars, clinical articles and online learning modules, case studies, audit and review programs and useful practice tools can all be accessed at nps.org.au/bdmards.
Valuable resources for consumers and carers
These are designed to assist consumers and health professionals in shared decision-making to get the best possible benefit from these medicines. They include action plans, patient decision aids and factsheets developed using the latest evidence, web resources including videos, an app, as well as information links to other relevant resources.